Recent News

• 11.09.2026 - Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
• 11.09.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 11.04.2026 - Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
• 11.03.2026 - Definium Therapeutics to Participate at Upcoming Investor Conferences
• 10.29.2026 - Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
• 10.26.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 10.13.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 09.28.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 09.14.2026 - Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
• 09.14.2026 - Definium Therapeutics Announces New Employee Inducement Grants

Recent Filings

• 11.09.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.09.2026 - EX-99.1 EX-99.1
• 11.09.2026 - 8-K Current report
• 11.05.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.25.2026 - 144 Report of proposed sale of securities